Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
41
NDRA Quote, Financials, Valuation and Earnings
Last price:
$5.06
Seasonality move
:
5.28%
Day range:
$4.91 - $5.08
52-week range:
$2.90 - $11.96
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.26x
P/B ratio:
34.57x
Volume:
10K
Avg. volume:
84.9K
1-year change:
-8.3%
Market cap:
$5.9M
Revenue:
--
EPS (TTM):
-$13.39
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NDRA
ENDRA Life Sciences, Inc.
|
-- | -$1.23 | -- | -84.08% | $30.00 |
|
AXGN
Axogen, Inc.
|
$57.2M | $0.07 | 17.39% | 556.06% | $35.44 |
|
ELMD
Electromed, Inc.
|
$17.8M | -- | 11.04% | -- | $36.00 |
|
IRIX
IRIDEX Corp.
|
$12.8M | -$0.12 | -2.72% | -18.18% | -- |
|
MYO
Myomo, Inc.
|
$10.8M | -$0.07 | -13.8% | -1168.66% | $5.00 |
|
STXS
Stereotaxis, Inc.
|
$9.2M | -$0.06 | 43.22% | -30.79% | $4.20 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NDRA
ENDRA Life Sciences, Inc.
|
$5.08 | $30.00 | $5.9M | -- | $0.00 | 0% | 3.26x |
|
AXGN
Axogen, Inc.
|
$32.80 | $35.44 | $1.5B | -- | $0.00 | 0% | 7.27x |
|
ELMD
Electromed, Inc.
|
$28.50 | $36.00 | $237.7M | 30.66x | $0.00 | 0% | 3.80x |
|
IRIX
IRIDEX Corp.
|
$1.23 | -- | $21.1M | -- | $0.00 | 0% | 0.41x |
|
MYO
Myomo, Inc.
|
$1.02 | $5.00 | $39.2M | -- | $0.00 | 0% | 1.00x |
|
STXS
Stereotaxis, Inc.
|
$2.46 | $4.20 | $229.6M | -- | $0.00 | 0% | 7.25x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NDRA
ENDRA Life Sciences, Inc.
|
75.4% | -1.699 | 12.41% | 0.99x |
|
AXGN
Axogen, Inc.
|
35.99% | -0.858 | 8.25% | 2.56x |
|
ELMD
Electromed, Inc.
|
-- | 1.217 | -- | 4.58x |
|
IRIX
IRIDEX Corp.
|
50.55% | 0.834 | 18.81% | 1.03x |
|
MYO
Myomo, Inc.
|
45.68% | -2.855 | 35.87% | 1.94x |
|
STXS
Stereotaxis, Inc.
|
32.62% | 1.831 | 1.93% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NDRA
ENDRA Life Sciences, Inc.
|
-$39.4K | -$1.4M | -265.94% | -318.69% | -- | -$1.2M |
|
AXGN
Axogen, Inc.
|
$46M | $1.9M | -1.19% | -1.94% | 3.18% | $1.4M |
|
ELMD
Electromed, Inc.
|
$13.2M | $2.7M | 18.88% | 18.89% | 15.81% | -$98K |
|
IRIX
IRIDEX Corp.
|
$4M | -$1.4M | -54.1% | -155.93% | -11.3% | -$1.2M |
|
MYO
Myomo, Inc.
|
$6.4M | -$3.5M | -46.49% | -68.35% | -34.86% | -$2.9M |
|
STXS
Stereotaxis, Inc.
|
$4.1M | -$5.2M | -141.59% | -218.3% | -69.75% | -$4.2M |
ENDRA Life Sciences, Inc. vs. Competitors
-
Which has Higher Returns NDRA or AXGN?
Axogen, Inc. has a net margin of -- compared to ENDRA Life Sciences, Inc.'s net margin of 1.18%. ENDRA Life Sciences, Inc.'s return on equity of -318.69% beat Axogen, Inc.'s return on equity of -1.94%.
Company Gross Margin Earnings Per Share Invested Capital NDRAENDRA Life Sciences, Inc.-- -$2.10 $696.7K AXGNAxogen, Inc.76.55% $0.01 $188.7M -
What do Analysts Say About NDRA or AXGN?
ENDRA Life Sciences, Inc. has a consensus price target of $30.00, signalling upside risk potential of 490.55%. On the other hand Axogen, Inc. has an analysts' consensus of $35.44 which suggests that it could grow by 8.06%. Given that ENDRA Life Sciences, Inc. has higher upside potential than Axogen, Inc., analysts believe ENDRA Life Sciences, Inc. is more attractive than Axogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NDRAENDRA Life Sciences, Inc.1 0 0 AXGNAxogen, Inc.7 0 0 -
Is NDRA or AXGN More Risky?
ENDRA Life Sciences, Inc. has a beta of -0.330, which suggesting that the stock is 132.966% less volatile than S&P 500. In comparison Axogen, Inc. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.241%.
-
Which is a Better Dividend Stock NDRA or AXGN?
ENDRA Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ENDRA Life Sciences, Inc. pays -- of its earnings as a dividend. Axogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NDRA or AXGN?
ENDRA Life Sciences, Inc. quarterly revenues are --, which are smaller than Axogen, Inc. quarterly revenues of $60.1M. ENDRA Life Sciences, Inc.'s net income of -$1.6M is lower than Axogen, Inc.'s net income of $708K. Notably, ENDRA Life Sciences, Inc.'s price-to-earnings ratio is -- while Axogen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ENDRA Life Sciences, Inc. is 3.26x versus 7.27x for Axogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NDRAENDRA Life Sciences, Inc.3.26x -- -- -$1.6M AXGNAxogen, Inc.7.27x -- $60.1M $708K
-
Which has Higher Returns NDRA or ELMD?
Electromed, Inc. has a net margin of -- compared to ENDRA Life Sciences, Inc.'s net margin of 12.65%. ENDRA Life Sciences, Inc.'s return on equity of -318.69% beat Electromed, Inc.'s return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital NDRAENDRA Life Sciences, Inc.-- -$2.10 $696.7K ELMDElectromed, Inc.78.15% $0.25 $44.7M -
What do Analysts Say About NDRA or ELMD?
ENDRA Life Sciences, Inc. has a consensus price target of $30.00, signalling upside risk potential of 490.55%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 26.32%. Given that ENDRA Life Sciences, Inc. has higher upside potential than Electromed, Inc., analysts believe ENDRA Life Sciences, Inc. is more attractive than Electromed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NDRAENDRA Life Sciences, Inc.1 0 0 ELMDElectromed, Inc.4 0 0 -
Is NDRA or ELMD More Risky?
ENDRA Life Sciences, Inc. has a beta of -0.330, which suggesting that the stock is 132.966% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.
-
Which is a Better Dividend Stock NDRA or ELMD?
ENDRA Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ENDRA Life Sciences, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NDRA or ELMD?
ENDRA Life Sciences, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. ENDRA Life Sciences, Inc.'s net income of -$1.6M is lower than Electromed, Inc.'s net income of $2.1M. Notably, ENDRA Life Sciences, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ENDRA Life Sciences, Inc. is 3.26x versus 3.80x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NDRAENDRA Life Sciences, Inc.3.26x -- -- -$1.6M ELMDElectromed, Inc.3.80x 30.66x $16.9M $2.1M
-
Which has Higher Returns NDRA or IRIX?
IRIDEX Corp. has a net margin of -- compared to ENDRA Life Sciences, Inc.'s net margin of -12.6%. ENDRA Life Sciences, Inc.'s return on equity of -318.69% beat IRIDEX Corp.'s return on equity of -155.93%.
Company Gross Margin Earnings Per Share Invested Capital NDRAENDRA Life Sciences, Inc.-- -$2.10 $696.7K IRIXIRIDEX Corp.32.15% -$0.09 $9.5M -
What do Analysts Say About NDRA or IRIX?
ENDRA Life Sciences, Inc. has a consensus price target of $30.00, signalling upside risk potential of 490.55%. On the other hand IRIDEX Corp. has an analysts' consensus of -- which suggests that it could grow by 62.6%. Given that ENDRA Life Sciences, Inc. has higher upside potential than IRIDEX Corp., analysts believe ENDRA Life Sciences, Inc. is more attractive than IRIDEX Corp..
Company Buy Ratings Hold Ratings Sell Ratings NDRAENDRA Life Sciences, Inc.1 0 0 IRIXIRIDEX Corp.0 0 0 -
Is NDRA or IRIX More Risky?
ENDRA Life Sciences, Inc. has a beta of -0.330, which suggesting that the stock is 132.966% less volatile than S&P 500. In comparison IRIDEX Corp. has a beta of 0.652, suggesting its less volatile than the S&P 500 by 34.842%.
-
Which is a Better Dividend Stock NDRA or IRIX?
ENDRA Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ENDRA Life Sciences, Inc. pays -- of its earnings as a dividend. IRIDEX Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NDRA or IRIX?
ENDRA Life Sciences, Inc. quarterly revenues are --, which are smaller than IRIDEX Corp. quarterly revenues of $12.5M. ENDRA Life Sciences, Inc.'s net income of -$1.6M is lower than IRIDEX Corp.'s net income of -$1.6M. Notably, ENDRA Life Sciences, Inc.'s price-to-earnings ratio is -- while IRIDEX Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ENDRA Life Sciences, Inc. is 3.26x versus 0.41x for IRIDEX Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NDRAENDRA Life Sciences, Inc.3.26x -- -- -$1.6M IRIXIRIDEX Corp.0.41x -- $12.5M -$1.6M
-
Which has Higher Returns NDRA or MYO?
Myomo, Inc. has a net margin of -- compared to ENDRA Life Sciences, Inc.'s net margin of -36.3%. ENDRA Life Sciences, Inc.'s return on equity of -318.69% beat Myomo, Inc.'s return on equity of -68.35%.
Company Gross Margin Earnings Per Share Invested Capital NDRAENDRA Life Sciences, Inc.-- -$2.10 $696.7K MYOMyomo, Inc.63.84% -$0.09 $26.9M -
What do Analysts Say About NDRA or MYO?
ENDRA Life Sciences, Inc. has a consensus price target of $30.00, signalling upside risk potential of 490.55%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that ENDRA Life Sciences, Inc. has higher upside potential than Myomo, Inc., analysts believe ENDRA Life Sciences, Inc. is more attractive than Myomo, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NDRAENDRA Life Sciences, Inc.1 0 0 MYOMyomo, Inc.4 0 0 -
Is NDRA or MYO More Risky?
ENDRA Life Sciences, Inc. has a beta of -0.330, which suggesting that the stock is 132.966% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.
-
Which is a Better Dividend Stock NDRA or MYO?
ENDRA Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ENDRA Life Sciences, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NDRA or MYO?
ENDRA Life Sciences, Inc. quarterly revenues are --, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. ENDRA Life Sciences, Inc.'s net income of -$1.6M is higher than Myomo, Inc.'s net income of -$3.7M. Notably, ENDRA Life Sciences, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ENDRA Life Sciences, Inc. is 3.26x versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NDRAENDRA Life Sciences, Inc.3.26x -- -- -$1.6M MYOMyomo, Inc.1.00x -- $10.1M -$3.7M
-
Which has Higher Returns NDRA or STXS?
Stereotaxis, Inc. has a net margin of -- compared to ENDRA Life Sciences, Inc.'s net margin of -86.59%. ENDRA Life Sciences, Inc.'s return on equity of -318.69% beat Stereotaxis, Inc.'s return on equity of -218.3%.
Company Gross Margin Earnings Per Share Invested Capital NDRAENDRA Life Sciences, Inc.-- -$2.10 $696.7K STXSStereotaxis, Inc.54.94% -$0.07 $17.1M -
What do Analysts Say About NDRA or STXS?
ENDRA Life Sciences, Inc. has a consensus price target of $30.00, signalling upside risk potential of 490.55%. On the other hand Stereotaxis, Inc. has an analysts' consensus of $4.20 which suggests that it could grow by 70.73%. Given that ENDRA Life Sciences, Inc. has higher upside potential than Stereotaxis, Inc., analysts believe ENDRA Life Sciences, Inc. is more attractive than Stereotaxis, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NDRAENDRA Life Sciences, Inc.1 0 0 STXSStereotaxis, Inc.3 0 0 -
Is NDRA or STXS More Risky?
ENDRA Life Sciences, Inc. has a beta of -0.330, which suggesting that the stock is 132.966% less volatile than S&P 500. In comparison Stereotaxis, Inc. has a beta of 1.472, suggesting its more volatile than the S&P 500 by 47.244%.
-
Which is a Better Dividend Stock NDRA or STXS?
ENDRA Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ENDRA Life Sciences, Inc. pays -- of its earnings as a dividend. Stereotaxis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NDRA or STXS?
ENDRA Life Sciences, Inc. quarterly revenues are --, which are smaller than Stereotaxis, Inc. quarterly revenues of $7.5M. ENDRA Life Sciences, Inc.'s net income of -$1.6M is higher than Stereotaxis, Inc.'s net income of -$6.5M. Notably, ENDRA Life Sciences, Inc.'s price-to-earnings ratio is -- while Stereotaxis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ENDRA Life Sciences, Inc. is 3.26x versus 7.25x for Stereotaxis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NDRAENDRA Life Sciences, Inc.3.26x -- -- -$1.6M STXSStereotaxis, Inc.7.25x -- $7.5M -$6.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
